01 March 2021 | News
Boehringer Ingelheim and Gubra Join forces to identify, validate, and uncover next-generation anti-obesity treatments
Photo Credit: Freepik
Boehringer Ingelheim and Gubra on March, 1st 2021 announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.
This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options.
“This marks the third joint research program between Boehringer Ingelheim and Gubra in the area of obesity since 2017. This latest research agreement further strengthens and complements Boehringer Ingelheim’s cardiometabolic portfolio” said Søren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim.
“We are particularly pleased about this third collaboration with Boehringer Ingelheim,” said Henrik Blou, CEO of Gubra. “Over the past four years our two companies have built a strong drug discovery relationship. In this third collaboration, Gubra is responsible for the early discovery of peptides – now applying our proprietary target and drug discovery platform streaMLine. After initial maturation, projects are handed over for further development to Boehringer Ingelheim. This approach, we believe, has the potential to take obesity treatment to the next level for the benefit of patients around the world.”
Under the terms of the agreement, Gubra is primarily responsible for early research activities. Boehringer Ingelheim will advance the programs further and bring promising candidates into non-clinical and clinical development. Financial terms of the new agreement are not disclosed.